Clinical Trial: Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices

Brief Summary:

Terlipressin is an effective and safe treatment for bleeding caused by rupture of oesophageal varices, which are life-threatening complications of liver cirrhosis.

Oesophageal varices are abnormal dilatation of veins occurring in the lower oesophagus, which can develop in patients with cirrhosis. Bleeding caused by rupture of these varices is a life-threatening complication with mortality between 20-50%.

Such bleeding can be treated with drug therapy and/or endoscopic; endoscopic therapy consists of a flexible tube equipped with a camera at the terminal end, allowing for visualizing and treating the oesophageal varices.

In this study, investigators will evaluate the safety and efficacy of terlipressin - Glypressin 1 mg, powder and solvent for solution for injection.

The non-interventional observational study "Follow-up of Glypressin (terlipressin) clinical efficacy in the treatment of bleeding oesophageal varices" aims to demonstrate that administration of Glypressin (terlipressin 1 mg) controls the bleeding in such patients.


Detailed Summary:
Sponsor: Ferring Pharmaceuticals

Current Primary Outcome:

  • To evaluate the clinical efficacy of Glypressin: measured by rapid control of heamorrhage; reduced mortality post-haemorrhage [ Time Frame: Up to 6 months ]
    Vital signs (blood pressure, heart rate, and body temperature) and routine safety lab analysis
  • To evaluate the safety profile of Glypressin: measured by number of patients with adverse events [ Time Frame: Up to 6 months ]


Original Primary Outcome: Same as current

Current Secondary Outcome: To evaluate/monitor the ease of administration in ER [ Time Frame: Up to 6 months ]

Easiness of use in ER (easy to reconstitute, easy to administer, flexible dosage)


Original Secondary Outcome: Same as current

Information By: Ferring Pharmaceuticals

Dates:
Date Received: April 7, 2011
Date Started: November 2010
Date Completion:
Last Updated: October 5, 2012
Last Verified: October 2012